January 06, 2023
2 min read
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
A study found no reported serious adverse events among children who received a COVID-19 vaccine after recovering from multisystem inflammatory syndrome in children, or MIS-C, according to results published in JAMA Network Open.
“There have been very limited data on the safety of COVID-19 vaccines in patients who had a history of MIS-C,” co-author Matthew D. Elias, MD, an attending at The Children’s Hospital of Philadelphia, told Healio.
A study found no reported serious adverse events among children who received a COVID-19 vaccine after recovering from MIS-C, according to results published in JAMA Network Open. Source: Adobe Stock.
Matthew Elias
“We all know COVID-19 vaccines are very helpful,” Elias said. “They decrease the risk of serious COVID-19 infection and decrease the risk of COVID-19 complications, including the risk of developing MIS-C itself, but there have been a lot of questions from families and health care professionals about whether the COVID- 19 vaccine would cause an abnormal immune response in patients with a history of MIS-C because MIS-C itself is involved with an abnormal immune response after COVID infection. So would this lead to recurrence of MIS-C? Would it lead to myocarditis after vaccination?”
The CDC recommends that patients with a history of MIS-C wait until they are clinically recovered and it has been at least 90 days since their diagnosis to receive a COVID-19 vaccine.
“No doubt that’s based on expert consensus, but there are very limited data, so our study aimed to address this issue,” Elias said.
Elias and colleagues conducted a cross-sectional study of patients enrolled at 22 North American centers participating in an NIH and National Heart, Lung, and Blood Institute-sponsored study called Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children (MUSIC). Eligible subjects included patients aged 5 years or older with a history of MIS-C more than 90 days after their MIS-C diagnosis. The patients filled out questionnaires about vaccination status and adverse reactions.
Of 385 eligible patients, 185 had received at least one vaccine dose, with 31 receiving a single dose, 142 receiving two doses and 12 receiving three doses. Most patients received Pfizer’s vaccine (347 of 351 doses).
Only 90 patients — about 48% of the vaccinated group — reported minor adverse reactions, which included poor soreness and fatigue. None reported any serious adverse events, including MIS-C recurrence or myocarditis.
“[The findings] were very reassuring, and honestly a sigh of relief,” Elias said. “I wouldn’t say that I was surprised by any of the results, but this was what I was certainly hoping to see.”
References:
CDC. Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States. https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf. Published Dec. 6, 2022. Accessed Jan 6, 2023.
COVID-19 vaccine for children after MIS-C appears safe. https://www.eurekalert.org/news-releases/975414. Published Jan 3, 2023. Accessed Jan 5, 2023.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
